- Stocks
- Healthcare
BCDA
BioCardia, Inc.
BCDA
NASDAQ·Healthcare·Biotechnology·Mkt cap $16.1M
$1.08
▼ -0.92%
P/E
-1.42
Mkt Cap
$16.1M
52-Wk Range
$0.75–$2.29
52-Week Range
$0.75 - $2.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 48.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Helix helical needle delivery technology for direct myocardial injection
- Advanced allogeneic bone marrow-derived mesenchymal stem cell platform
- Experienced management team in regenerative medicine and cardiac therapeutics
- Patent-protected intellectual property in cell therapy delivery mechanisms
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Clinical trial progression for CardiAMP Cell Therapy in heart failure treatment
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BCDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.13 vs -$0.18 consensus (+27.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.8%
Revenue trend · last 8Q
—
—
-100%
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BCDA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related